Compare MAR & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAR | BMY |
|---|---|---|
| Founded | 1927 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7B | 113.5B |
| IPO Year | 2005 | N/A |
| Metric | MAR | BMY |
|---|---|---|
| Price | $368.75 | $60.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $359.31 | $61.73 |
| AVG Volume (30 Days) | 1.5M | ★ 11.4M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | 0.76% | ★ 4.38% |
| EPS Growth | ★ 14.17 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $26,186,000,000.00 | N/A |
| Revenue This Year | $304.38 | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $151.51 | ★ $17.26 |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $253.76 | $42.52 |
| 52 Week High | $410.98 | $62.89 |
| Indicator | MAR | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 44.84 | 60.21 |
| Support Level | $362.71 | $56.46 |
| Resistance Level | $384.12 | $61.16 |
| Average True Range (ATR) | 7.63 | 1.49 |
| MACD | -0.64 | 0.36 |
| Stochastic Oscillator | 35.21 | 74.06 |
Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.